Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a record-shattering $240 billion in total M&A investment in 2025, represents a fundamental shift in how
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade ago, the British-Swedish multinational has transformed into a high-growth oncology and rare disease powerhouse. With a market capitalization now rivaling the [...]
The fourth-quarter earnings season of 2025 has reached a fever pitch, delivering a resounding message of resilience to Wall Street. As of February 6, 2026, the S&P 500 has reported an aggregate year-over-year earnings growth of 10.1%, a figure that has silenced skeptics who feared a late-cycle slowdown.
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company’s supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) with hemophilia A or B without inhibitors. In the U.S., HYMPAVZI is currently approved for the treatment of patients 12 years of age and older with hemophilia A without factor VIII (FVIII) inhibitors, or hemophilia B without factor IX (FIX) inhibitors.
Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer’s broader landmark Most Favored Nation (MFN) agreement with the U.S. government enabling patients to pay lower prices for their prescription medicines, while strengthening America’s role as a global leader in pharmaceutical innovation.
The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of semiconductors, automobiles, and pharmaceuticals. These measures, framed as essential for national security and domestic industrial revitalization, have sent shockwaves
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a staggering 45% surge in full-year 2025 revenue, propelled by the insatiable global demand for its blockbuster treatments,
The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes medicine Januvia.
As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization threshold, the Indianapolis-based pharmaceutical giant has transitioned from a legacy drugmaker into a high-growth biotechnology powerhouse. Driven primarily by its leadership in the incretin space—specifically [...]
Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue to be around $61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.66 per share was 16.2% above analysts’ consensus estimates.
